Bonus BioGroup
Business Services · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Madain Industries Center PO Box 15143, H...Phone Number
+972 732067100Website
www.bonus-bio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Bonus BioGroup
Bonus Biogroup is a clinical-stage biotechnology company focused on pioneering regenerative medicine through the development of tissue engineering and cell therapy products. Their innovative solutions, including MesenCure and BonoFill, aim to address unmet medical needs related to tissue damage, inflammation, and immune response. The company targets a wide range of clients, including patients with severe conditions and healthcare professionals seeking advanced treatment options. Ongoing clinical trials are evaluating the safety and efficacy of their investigational therapies.Explore more
Popular SearchesBonus BiogroupBonus Biogroup LtdBonus BioGroup| LtdBonusbiogroupto Bonus BioGroup LtdSIC Code 87,873NAICS Code 54,541Show moreBonus BioGroup Org Chart
Get the full picture
Sign in to uncover key details.
VK
Vice President, Regulatory & Clinical Affairs
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bonus BioGroup your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Bonus BioGroup
Click to see if Bonus BioGroup had a recent Job posting/layoffs
Check if Bonus BioGroup has recently received funding, and reach out quickly before it becomes old news!
Bonus BioGroup, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Bonus BioGroup recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Bonus BioGroup is spiking on competitors!
Product Launch: Get notified when Bonus BioGroup launches new products
Funding: Get notified immidiatlly once Bonus BioGroup has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Bonus BioGroup is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bonus BioGroup is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bonus BioGroup.
Bonus BioGroup Tech Stack
Bonus BioGroup News & Media
Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress
The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute respiratory distress syndrome (ARDS)Bonus BioGroup's COVID Drug - MesenCure - Can Help a Life-threatening Complication Seen in Cancer Patients
Bonus BioGroup (TASE: BONS), a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, has discovered that its COVID drug, MesenCure, can also reduce inflammatory overreaction seen in cancer patients...Bonus BioGroup Submits Outstanding Phase-II Trial Results for MesenCure, a Treatment for ...
Tel Aviv, Israel--(Newsfile Corp. - January 18, 2022) - Bonus BioGroup (TASE: BONS) or "the Company", a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, submitted results for its multicenter, Phase-II clinical trial to the Israeli Ministry of Health on January 9th. Following on the heels of the Company's initial release of encouraging preliminary results in November 2021, the trial data submitted lastBonus BioGroup Submits Outstanding Phase-II Trial Results for MesenCure, a Treatment for Severe COVID-19, to the Israeli Ministry of Health
Tel Aviv, Israel--(Newsfile Corp. - January 18, 2022) - Bonus BioGroup (TASE: BONS) or "the Company", a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, submitted results for its multicenter, Phase-II clinical trial to the Israeli Ministry of Health on January 9th. Following on the heels of the Company's initial release of encouraging preliminary results in November 2021, the trial data submitted last
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bonus BioGroup
Sign Up For FreeTo access detailed company insights
Bonus Biogroup is a clinical-stage biotechnology company focused on pioneering regenerative medicine through the development of tissue engineering and cell therapy products. Their innovative solutions, including MesenCure and BonoFill, aim to address unmet medical needs related to tissue damage, inflammation, and immune response. The company target... Read More
